49,006
edits
Difference between revisions of "Urothelial carcinoma"
Jump to navigation
Jump to search
no edit summary
| (2 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
| IHC = [[GATA3]] +ve, p63 +ve, CK5/6 +ve, CK34betaE12 +ve, PSA -ve | | IHC = [[GATA3]] +ve, p63 +ve, CK5/6 +ve, CK34betaE12 +ve, PSA -ve | ||
| EM = | | EM = | ||
| Molecular = not used for diagnosis; typically: 9p deletions, 17p deletions | | Molecular = not used for diagnosis; typically: 9p deletions, 17p deletions; can be [[Classification of urothelial carcinoma by immunohistochemistry|subclassified with IHC]]; [[FGFR2/FGFR3]] mutations | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Grossing = [[radical cystectomy grossing]], [[cystoprostatectomy grossing]], [[nephroureterectomy grossing]] | | Grossing = [[transurethral resection of bladder tumour grossing]], [[radical cystectomy grossing]], [[cystoprostatectomy grossing]], [[nephroureterectomy grossing]] | ||
| Staging = [[bladder cancer staging]] | | Staging = [[bladder cancer staging]] | ||
| Site = [[urothelium]] - [[ureter]], [[urinary bladder]], proximal [[urethra]] (see [[urothelial carcinoma of the urethra]], renal pelvis | | Site = [[urothelium]] - [[ureter]], [[urinary bladder]], proximal [[urethra]] (see [[urothelial carcinoma of the urethra]], renal pelvis | ||
| Line 152: | Line 152: | ||
=Molecular= | =Molecular= | ||
* | *Molecular testing usually ''not'' used for diagnosis. | ||
**Molecular subtyping can be approximated with immunostaining - see ''[[Classification of urothelial carcinoma by immunohistochemistry]]''. | |||
Changes: | Changes: | ||
*9p deletion -- site of CDKN2A<ref name=omim600160>{{OMIM|600160}}</ref> (AKA p16). | *9p deletion -- site of CDKN2A<ref name=omim600160>{{OMIM|600160}}</ref> (AKA p16). | ||
*17p deletion -- site of PT53 (AKA p53). | *17p deletion -- site of PT53 (AKA p53). | ||
=Sign out= | =Sign out= | ||